Abstract
Objective To evaluate the effects of nanosecond pulsed electric fields (nsPEFs) with different pulse durations in cell vitality, apoptosis, and proliferation of TPC-1 cells, optimize pulse parameters and expand the application range of nsPEFs. Methods The pulse duration of 0, 300 ns, 500 ns, and 900 ns is generated with nsPEF generator. CCK-8 was used to investigate the effect of nsPEFs on the viability of TPC-1 cells. Flow cytometry was used to evaluate the apoptosis of TPC-1 after pulse treatment. The effect of nsPEFs on the proliferation ability of TPC-1 cells was detected by 5-ethy-nyl-2′-deoxyuridine. The morphological changes of TPC-1 cells after pulse treatment were observed by transmission electron microscopy. Results NsPEFs with 900 ns pulse duration can significantly affect the viability of TPC-1 cells and inhibit the proliferation ability of TPC-1 cells. In addition, nsPEFs can also induce apoptosis of TPC-1 cells. Conclusion NsPEFs with longer pulse duration can significantly affect the biological behavior of TPC-1 cells, such as cell viability and proliferation ability, and can also induce cell apoptosis, thereby inhibiting cell growth.
Highlights
Thyroid cancer is transformed from thyroid follicular cells derived from the endoderm or thyroid C cells derived from the neural crest [1]
In order to further expand the application scope of nanosecond pulsed electric fields (nsPEFs) and promote the preclinical study of nsPEFs in humans, we explored the influence of nsPEFs with different pulse duration in cell vitality, apoptosis, and proliferation of TPC-1 cells
By CCK-8, we detected the viability of TPC-1 cells at 24 h, 48 h, and 72 h after nsPEF treatment
Summary
Thyroid cancer is transformed from thyroid follicular cells derived from the endoderm or thyroid C cells derived from the neural crest [1]. According to the origin and differentiation of tumors, thyroid cancer can be divided into papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, medullary thyroid carcinoma, and anaplastic thyroid cancer. By far the most common form, PTC contains the classic form and 14 variants, including the high-cell and follicular variants [2], which account for approximately 85 percent of thyroid cancers [3]. Over the past 20 years, the incidence of invasive PTC has increased by 9.1%. Due to the inherent high degree of late symptomatic disease, the sharp increase in the incidence of invasive PTC is unlikely to come from the subclinical pool [5]. Classical or high-cell variant papillary thyroid cancers with BRAF mutations show a high frequency of lymph node metastasis and recurrence after thyroidectomy and respond poorly to radiation iodine therapy [6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
